Valbiotis SA (EPA:ALVAL)

France flag France · Delayed Price · Currency is EUR
0.970
-0.002 (-0.21%)
Apr 28, 2026, 5:35 PM CET
-4.53%
Market Cap 22.95M
Revenue (ttm) 905.00K
Net Income (ttm) -9.42M
Shares Out 23.66M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,118
Average Volume 145,089
Open 0.976
Previous Close 0.972
Day's Range 0.962 - 0.989
52-Week Range 0.535 - 1.296
Beta -0.21
RSI 44.33
Earnings Date Jun 26, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Valbioti... [Read more]

Industry Packaged Foods
Founded 2014
Employees 50
Stock Exchange Euronext Paris
Ticker Symbol ALVAL
Full Company Profile

Financial Performance

In 2025, Valbiotis's revenue was 905,000, an increase of 414.20% compared to the previous year's 176,000. Losses were -9.42 million, -6.06% less than in 2024.

Financial Statements

News

There is no news available yet.